Research programme: matrix metalloproteinase inhibitors - Cengent Therapeutics/De NovoAlternative Names: MMP inhibitors - Cengent Therapeutics/De Novo
Latest Information Update: 31 Aug 2007
At a glance
- Originator Cengent Therapeutics; De Novo Pharmaceuticals
- Mechanism of Action Matrix metalloproteinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Inflammation
Most Recent Events
- 31 Aug 2007 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)
- 31 Aug 2007 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 31 Aug 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)